A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT06234605

Public ClinicalTrials.gov record NCT06234605. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Study identification

NCT ID: NCT06234605
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: HiberCell, Inc.; Industry
Enrollment: 80 participants

Conditions and interventions

Conditions

Renal Cell Carcinoma

Interventions

HC-7366 Drug
Belzutifan Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 28, 2024
Primary completion: Oct 31, 2026
Completion: Oct 31, 2027
Last update posted: Jan 14, 2026

2024 – 2027

United States locations

U.S. sites: 20
U.S. states: 14
U.S. cities: 17

Facility	City	State	ZIP	Site status
University of Arizona Cancer Center	Tucson	Arizona	85719	Recruiting
University of California San Diego Moores Cancer Center	La Jolla	California	92093	Recruiting
Cedars-Sinai Medical Center	Los Angeles	California	90048	Recruiting
University of Colorado Anschutz Medical Campus	Aurora	Colorado	80045	Recruiting
Rocky Mountain Cancer Centers, LLP	Lone Tree	Colorado	80124	Recruiting
Yale - New Haven Hospital	New Haven	Connecticut	06520	Recruiting
HealthPartners Cancer Research Center	Saint Paul	Minnesota	55101	Recruiting
Washington University School of Medicine	St Louis	Missouri	63110	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
University Hospitals Cleveland Medical Center	Cleveland	Ohio	44106	Recruiting
Cleveland Clinic	Cleveland	Ohio	44195	Recruiting
Providence Cancer Institute	Portland	Oregon	97213	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
Texas Oncology	Dallas	Texas	75246	Recruiting
University of Texas Southwestern Medical Center	Dallas	Texas	75390	Recruiting
University Medical Center & Texas Tech Health Science Center	Lubbock	Texas	79430	Recruiting
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting
Swedish Medical Center	Seattle	Washington	98104	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting
University of Wisconsin - Carbone Cancer Center	Madison	Wisconsin	53705	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06234605, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 14, 2026 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06234605 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →